This invention relates generally to implantable chronic medical electrical leads and methods of use, and more particularly to an implantable neural lead for chronic stimulation of the cerebral cortex of the brain and method of use.
Stimulation of the motor cortex is currently a promising therapy to treat deafferentation pain syndromes, including but not limited to central deafferentation pain arising from stroke, infection, trauma, spinal cord injury, multiple sclerosis, and peripheral pain syndromes including but not limited to trigeminal neuralgia, atypical facial pain, pain arising from peripheral nerve injury or disease including but not limited to nerve plexus avulsion, phantom limb pain, etc. Furthermore, stimulation of the motor cortex or other areas of the cerebral cortex of the brain are potentially promising therapies for treatment of other neurological disorders including, but not limited to movement disorders, neurodegenerative disorders, psychological disorders, and epilepsy, and other central and peripheral disorders.
To date, the best results of chronic motor cortex stimulation for pain have been obtained when stimulation was applied precisely to the zone of motor cortex corresponding to the part of the body in which the pain is experienced. It is therefore essential to respect the somatotopic organization of the motor cortex. The combination of imaging techniques including but not limited to Computerized Axial Tomography (CAT) scans, Magnetic Resonance Imaging (MRI), and three-dimensional neuronavigation procedures for anatomical localization and intraoperative anatomical and electrophysiological testing can greatly improve localization of the zone to be stimulated, thereby improving the clinical results. The objective is to ensure that at least one of the active electrodes is directly over the desired zone of stimulation.
The motor cortex is a narrow band of cortex situated in the precentral gyrus immediately anterior to the central sulcus. The Resume® lead (four electrodes arranged in linear fashion) manufactured by Medtronic, Inc., has been used for chronic stimulation of the motor cortex. If a Resume® lead is placed parallel to the central sulcus, several adjacent zones of the motor cortex can be stimulated simultaneously allowing the treatment of extensive pain, for example involving the entire hemibody. However, as the motor cortex is fairly narrow in the antero-posterior direction and follows the sometimes pronounced convolutions of the central sulcus, the electrode may be inadvertently placed anteriorly or posteriorly to the desired location. It is therefore preferred to place the Resume® lead perpendicularly to the central sulcus in order to ensure at least one of the four contacts of the electrode is directly over the motor cortex. The essential difficulty is to very precisely locate the “height” or mediolateral zone of representation of the part of the body affected by the pain. This localization requires the use of several modalities: imaging data and intra-operative somaesthetic evoked potentials (SEP), and clinical results (muscle contractions) of motor cortex stimulation. Even with these techniques, the limited coverage of this electrode makes it difficult to treat pain involving larger or more extensive regions of the body.
In addition, the method of localization and then implantation of the chronic Resume lead involved two major steps. First, the localization using the modalities mentioned above was performed including the use of a temporary grid of multiple electrodes such as those made by Ad-Tech Medical Instrument Corporation. Once the localization step is completed, the temporary grid electrodes are removed and replaced with a Resume® lead. (In some cases two Resume® leads have been implanted for chronic motor cortex stimulation.) This removal and replacement step adds a layer of complexity and risk of error to the surgical procedure because it requires very precise placement of the chronic lead following removal of the temporary multi-electrode grid used for localization. This step also increases potential short and long-term risks to the patient and extends procedure time. Moreover, financial expense is incurred by the need for both a temporary lead and a chronic or permanent lead.
The location of the paddle when stimulating the motor cortex or elsewhere on the cerebral cortex is beneath the cranium while the lead body is outside of, and must pass through, the cranium. This transition zone over the thickness of the cranium results in mechanical strain between the paddle and the lead body. This strain makes it more difficult to get and keep the entire lead paddle in contact with the tissue being stimulated, and creates risk to the integrity of the lead insulation and conductors.
In a first embodiment, an implantable neural lead for use in electrically stimulating the cerebral cortex is provided. The neural lead includes a paddle, a lead body and a strain relief. The strain relief connects the paddle with the lead body and offsets the lead body from the paddle to accommodate the thickness of the patient's cranium.
In a second embodiment, an implantable neural lead for use in stimulating the cerebral cortex of the brain is provided. This embodiment lead includes a lead body and a paddle. The paddle has a two-dimensional electrode array with two sets of electrodes. The first set of electrodes of at least three is in a line defining an axis of the paddle. The second set of electrodes are offset in opposite directions from the axis of the paddle.
In a third embodiment, an implantable neural lead for use in electrically stimulating the cerebral cortex is provided. This embodiment neural lead includes a lead body and a lead paddle. The paddle includes a two-dimensional array of electrodes. The paddle lead also includes a peripheral edge that defines at least two peninsulas and at least two bays.
In a fourth embodiment, a method of treating a neurological disorder by electrical stimulation of the cerebral cortex is provided. The method includes providing an implantable neural lead, creating an opening through skull bone to access an area adjacent the cortex, placing the lead paddle within the area, determining a satisfactory orientation for the lead paddle, permanently attaching the lead paddle within the area for chronic stimulation, and implanting a pulse generator in electrical communication with the lead.
In a fifth embodiment, a method of treating a neurological disorder by electrical stimulation of the cerebral cortex is provided. This embodiment method includes providing an implantable neural lead, creating an opening in the skull bone to access an area adjacent the cortex, placing the lead paddle within the area, determining whether stimulation with the first set of electrodes provides sufficient relief, based on the previous step implanting either a single or a dual channel stimulator.
Referring to
Neural lead 100 may be used to treat any neurological disorder for which stimulation of the cortex of the brain has therapeutic value. Some example neurological disorders for use of the neural lead of this invention include, but are not limited to, treatment of pain such as facial, neck, limbic or other pain, movement disorders such as Parkinson's disease, essential tremor and dystonia, psychological disorders such as depression and obsessive compulsive disorder (OCD), epilepsy, Huntington's Disease, and neurodegenerative disorders. It is noted that pain is considered a neurological disorder for purposes of this application.
Neural lead 100 may be placed epidurally (outside the dura mater) or subdurally (beneath the dura mater). For example, in the case of treatment of pain the lead is likely to be used epidurally. In the case of epilepsy it is more likely that the lead would be used subdurally. In either case a craniotomy is performed and the paddle 102 placed beneath the cranium. In one application, lead 100 is placed epidurally adjacent the central sulcus of the cortex for stimulation to treat pain such as facial, neck or limbic pain.
Strain Relief
One of the novel features of the neural lead of the present invention is a strain relief. For purposes of this application, a strain relief is defined as a section of a lead that exists between a lead body or extension and a paddle and that displaces the lead body or extension some distance or offset from the paddle to accommodate generally the thickness of a patient's cranium. The strain relief allows the lead body or extension to lie above the cranium and the paddle to be situated beneath the cranium while reducing the amount of strain or pull between the paddle and the lead body or extension because of the displacement between the paddle and the lead body or extension.
One embodiment strain relief 108 is shown in
As shown in
In the embodiment shown, the strain relief 108 is attached to the lead paddle 102 along the peripheral edge 112 of the paddle 102. The distal ends 111, 113 of the lead bodies 106, 107 are attached to the strain reliefs 108, 109 respectively.
As shown in
As shown in
Preferably, the strain reliefs 108, 109 offset the lead bodies 106, 107 from the first major surface 114 by a distance of between about 4 mm and 10 mm. More preferably, the offset is about 6 mm.
A rongeur may be used to make notches (not shown) in either the bone flap or the cranium to accommodate the strain reliefs 108, 109 when there is misalignment between the craniotomy and the stimulation site. The gap between the strain reliefs 108, 109 and the notches will eventually fill with new bone isolating all but the portion of each strain relief that lies on the cranium from any flexing due to lead body movement. The physician will position the notches such that they direct the strain reliefs 108 and 109 and the lead bodies 106 and 107 toward the location of the eventual tunnel for the extension. In an alternative embodiment, the strain reliefs or lead bodies may also be anchored or sutured outside the cranium for further reduction of flexing.
The definition of a strain relief can include a strain relief connector. A strain relief connector is defined as a strain relief that includes a connector. The connector could be a female or male or any other type of connector for connecting a paddle to an extension.
It is noted that the strain relief of this invention could be used with any type of paddle lead including one or two-dimensional paddle leads. A one-dimensional paddle lead is defined for this application as being a paddle lead that has a plurality of electrodes in a line and no electrodes out of alignment with the line. A two-dimensional paddle lead is defined for this application as being a paddle lead with three or more electrodes positioned in such a way that they are not all in a line. A two-dimensional paddle lead includes a lead with a line of electrodes and one electrode out of alignment with the line. For purposes of this application, a two-dimensional paddle lead also includes non-planar orientation of electrodes.
An alternate embodiment lead of the present invention could include only a single lead body and single strain relief. In such an embodiment, all of the conducting wires would pass through the single lead body and strain relief instead of being separated as shown in
Electrode Configuration
The number of electrodes 104 as well as the position of the electrodes 104 on the paddle 102 may vary greatly within the scope of the present invention. In one particularly advantageous embodiment, the lead paddle 102 has a two dimensionally distributed electrode array including a plurality of electrically isolated electrodes, the plurality of electrodes including a first set of at least three electrodes defining an axis of the paddle and a second set of electrodes offset in opposite directions from the axis of the paddle. For example, the first set of electrodes in
The lead shown in
The neural lead of this invention may be used with any pulse generator.
In the embodiment shown in
Paddle Dimensions
In a preferred embodiment, the diameter and thickness of the paddle are 1.575 inches and 0.054 inches, respectively. Other preferred dimensions are shown in
Paddle Shape
The shape of the paddle may be round as shown in
Method of Treating a Neurological Disorder
Due to the distribution of the electrodes 104, the lead 100, 200 or 300 can also be used for intraoperative detection, as these 8 electrode leads can be used to record somaesthetic evoked potentials, which confirm the position of the central sulcus. Similarly, this same electrode can be used to stimulate the cortex intraoperatively in order to confirm the position of the various functional zones of the motor cortex. This technique should therefore represent a major financial economy, since a fairly costly disposable electrode with several contacts previously had to be used for electrophysiological detection, while the Resume® lead was used for chronic stimulation. Also the use of the lead of this invention for both localization and chronic stages eliminates a layer of complexity to the surgical operation reduces potential for placement error, reduces short and long-term risks to the patient, reduces procedure time, and makes the procedure more economical
An exemplary embodiment method of treating a neurological disorder is shown in
As indicated by block 502, a circular craniotomy, 4 to 5 cm in diameter, is performed with the guidance of the neuronavigation system. The 8-electrode paddle is placed on the dura mater and connected to a somaesthetic evoked potential (SEP) recording apparatus as shown in blocks 504 and 506.
The position of the lead over the central sulcus is confirmed by correlating the anatomical detection data (neuronavigation) with the SEP data obtained after stimulation of the median nerve at the wrist as shown in block 508.
As shown in block 510, the position of the various functional zones of the motor cortex can be confirmed by stimulating the electrodes supposedly situated directly over the motor cortex and observing the response. For example, in order to treat facial pain, the zone of motor cortex for which stimulation induces muscle contractions of the face is identified.
As indicated in block 512, the lead is then attached to the dura mater by several sutures. Other attachment methods may be used such as anchors or other methods known in the art.
When anatomical and electrophysiological data are concordant and very clear, the two leads of the electrode are connected during the same operation to an IPG.
Depending on the results of the above trials and screening, the next step shown as block 514 involves a determination of whether a single channel IPG such as a Soletra® stimulator or a dual channel stimulator such as a Synergy® stimulator is preferred. If use of electrodes 0, 1, 2, and 3 are sufficient to alleviate pain or otherwise reduce symptoms of the disorder, then a single channel stimulator is sufficient. If use of the other electrodes 4, 5, 6, or 7 provides further reduction in symptoms, then a dual channel stimulator may be preferred.
As indicated in block 516, the selected stimulator is then implanted in electrical communication with the electrodes 104.
When there is a doubt about efficacy based on location or other factors, due to a discrepancy between anatomical and electrophysiological data, the leads may be exteriorized and a clinical test performed during the days following the operation. A single channel or dual channel stimulator may then be implanted depending on the clinically effective electrodes.
Thus, embodiments of the implantable cortical neural lead and method are disclosed. One skilled in the art will appreciate that the present invention can be practiced with embodiments other than those disclosed. The disclosed embodiments are presented for purposes of illustration and not limitation, and the present invention is limited only by the claims that follow.
Number | Name | Date | Kind |
---|---|---|---|
3724467 | Avery et al. | Apr 1973 | A |
4092985 | Kaufman | Jun 1978 | A |
4603696 | Cross, Jr. et al. | Aug 1986 | A |
4869255 | Putz | Sep 1989 | A |
4907597 | Chamoun | Mar 1990 | A |
5044368 | Putz | Sep 1991 | A |
5097835 | Putz | Mar 1992 | A |
5136687 | Edelman et al. | Aug 1992 | A |
5143081 | Young et al. | Sep 1992 | A |
5269303 | Wernicke et al. | Dec 1993 | A |
5417719 | Hull et al. | May 1995 | A |
5484445 | Knuth | Jan 1996 | A |
5702429 | King | Dec 1997 | A |
5711316 | Elsberry et al. | Jan 1998 | A |
5713922 | King | Feb 1998 | A |
5865842 | Knuth et al. | Feb 1999 | A |
5938688 | Schiff | Aug 1999 | A |
6006124 | Fischell et al. | Dec 1999 | A |
6038480 | Hrdlicka et al. | Mar 2000 | A |
6058331 | King | May 2000 | A |
6066163 | John | May 2000 | A |
6091979 | Madsen | Jul 2000 | A |
6094598 | Elsberry et al. | Jul 2000 | A |
6096510 | Hochman | Aug 2000 | A |
6128537 | Rise | Oct 2000 | A |
6171239 | Humphrey | Jan 2001 | B1 |
6227203 | Rise et al. | May 2001 | B1 |
6253109 | Gielen | Jun 2001 | B1 |
6263237 | Rise | Jul 2001 | B1 |
6319241 | King et al. | Nov 2001 | B1 |
6356784 | Lozano et al. | Mar 2002 | B1 |
6356788 | Boveja | Mar 2002 | B1 |
6366813 | DiLorenzo | Apr 2002 | B1 |
6463328 | John | Oct 2002 | B1 |
6473653 | Schall Horn et al. | Oct 2002 | B1 |
6484059 | Gielen | Nov 2002 | B1 |
6517361 | Yatskov et al. | Feb 2003 | B1 |
6539263 | Schiff et al. | Mar 2003 | B1 |
6573063 | Hochman | Jun 2003 | B1 |
20010003799 | Baveja | Jun 2001 | A1 |
20010008972 | Gielen | Jul 2001 | A1 |
20010029391 | Gluckman et al. | Oct 2001 | A1 |
20020016638 | Mitra et al. | Feb 2002 | A1 |
20020035377 | Bardy et al. | Mar 2002 | A1 |
20020087201 | Firlick et al. | Jul 2002 | A1 |
20020091419 | Firlik et al. | Jul 2002 | A1 |
20020116030 | Rezai | Aug 2002 | A1 |
20020128700 | Cross, Jr. | Sep 2002 | A1 |
20020151939 | Rezai | Oct 2002 | A1 |
20020177882 | DiLorenzo | Nov 2002 | A1 |
20020183817 | Van Venrooij et al. | Dec 2002 | A1 |
20030050569 | Shenoy et al. | Mar 2003 | A1 |
20030074032 | Gliner | Apr 2003 | A1 |
20030078522 | Mitra et al. | Apr 2003 | A1 |
20030088274 | Gliner et al. | May 2003 | A1 |
20030097159 | Schiff et al. | May 2003 | A1 |
20030097161 | Firlik et al. | May 2003 | A1 |
20030100931 | Mullett | May 2003 | A1 |
20030125786 | Gliner et al. | Jul 2003 | A1 |
20030130706 | Sheffield | Jul 2003 | A1 |
20030149457 | Tcheng et al. | Aug 2003 | A1 |
20030204228 | Cross et al. | Oct 2003 | A1 |
20050131506 | Rezai et al. | Jun 2005 | A1 |
Number | Date | Country |
---|---|---|
0 998 958 | May 2000 | EP |
WO 9739797 | Oct 1997 | WO |
WO 9920342 | Apr 1999 | WO |
WO 0007494 | Feb 2000 | WO |
WO 0009008 | Feb 2000 | WO |
WO 0076580 | Dec 2000 | WO |
WO 0137717 | May 2001 | WO |
WO 0141867 | Jun 2001 | WO |
WO 0245795 | Jun 2002 | WO |
WO 03066154 | Aug 2002 | WO |
WO 02072194 | Sep 2002 | WO |
WO 03026738 | Apr 2003 | WO |
WO 03026739 | Apr 2003 | WO |
WO 03035163 | May 2003 | WO |
WO 03041559 | May 2003 | WO |
WO 03055556 | Jul 2003 | WO |
WO 03063949 | Aug 2003 | WO |
WO 03066157 | Aug 2003 | WO |
WO 03066162 | Aug 2003 | WO |
WO 03082402 | Oct 2003 | WO |
WO 04052448 | Jun 2004 | WO |
Number | Date | Country | |
---|---|---|---|
20040243205 A1 | Dec 2004 | US |